Specifically, increases seen in irritable bowel syndrome and chronic idiopathic constipation
WEDNESDAY, July 9, 2025 (HealthDay News) — There was an increase in disorders of gut-brain interaction (DGBI) during the COVID-19 pandemic for those living in the United States, according to a study recently published online in Neurogastroenterology & Motility.
Christopher V. Almario, M.D., from Cedars-Sinai in Los Angeles, and colleagues assessed trends in the prevalence of Rome IV gastroduodenal and bowel DGBI over time based on survey responses from a nationally representative sample of more than 160,000 U.S. adults.
The researchers found that during the COVID-19 pandemic, the prevalence of irritable bowel syndrome (IBS) increased (6.1 [May 2020] to 11.0 percent [May 2022]; +0.188 percent/month), as did chronic idiopathic constipation (6.0 [May 2020] to 6.4 percent [May 2022]; +0.056 percent/month). The largest prevalence increase was seen in mixed IBS (+0.085 percent/month), IBS with constipation (+0.041 percent/month), and IBS with diarrhea (+0.037 percent/month). For the other examined gastroduodenal and bowel DGBI, there were no changes in prevalence.
“These findings underscore the significant toll the pandemic has taken on digestive health,” Almario said in a statement. “These disorders involve chronic gastrointestinal symptoms that are often triggered or worsened by psychological stress.”
Several authors disclosed ties to relevant organizations.
Abstract/Full Text (subscription or payment may be required)
Mental Distress, Fatigue Common in Childhood Survivors of Leukemia, Lymphoma
Antibiotic Prescribing >95 Percent for Uncomplicated Diverticulitis
Gut Microbial, Metabolomic Alterations Persist After Adenoma Resection
Risk Factors Associated With Child Food Allergy Identified
Study IDs Dementia Risk Factors in Those Older Than 90 Years
Omalizumab, Multiallergen OIT Both Viable for Multifood Allergy Treatment
Early-Life PFAS Exposure Tied to Intestinal Inflammation in Childhood
CDC: Seroprevalence of Alpha-Gal IgE Antibodies Highest in States With Elevated Case Counts